On January 3, 2001, the Cancer Assessment Review Committee met to discuss the carcinogenic potential of Fluazinam. During this meeting, the committee requested Peto's prevalence test analyses of the male rat thyroid follicular cell tumors. Though there were no significant survival disparities among the dose groups, the mortality of the controls was 15% higher than that of the male high dose group (Fluazinam Qualitative Risk Assessment Based On Sprague-Dawley Rat and CD-1 Mouse Dietary Studies, L. Brunsman, 12/13/2000). The results of the Peto's prevalence test analyses are presented in this memo.

Background

A combined chronic toxicity and oncogenicity study in Sprague-Dawley rats was conducted by Huntingdon Research Centre, Ltd., Cambridgeshire, England, for Ishihara Sangyo Kaisha, Ltd., Tokyo, Japan, and dated August 25, 1988 (Report No. ISK 8/87263; MRID No. 42248620).

The study design allocated groups of 50 rats per sex to dose levels of 0, 1, 10, 100 or 1000 ppm of Fluazinam for 104 weeks. An additional 10 rats per sex per dose were designated for interim sacrifice at week 52.
Tumor Analyses

Male rats had a significant increasing trend in thyroid gland follicular cell carcinomas at p < 0.05. There was a significant difference in the pair-wise comparison of the 1000 ppm dose group with the controls for thyroid gland follicular cell adenomas and/or carcinomas combined at p < 0.05.
Table 1. Fluazinam - Sprague-Dawley Rat Study

Male Thyroid Gland Follicular Cell Tumor Rates and Peto's Prevalence Test Results (p values)

<table>
<thead>
<tr>
<th>Dose (ppm)</th>
<th>0</th>
<th>1</th>
<th>10</th>
<th>100</th>
<th>1000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenomas (%)</td>
<td>4/46</td>
<td>3/33</td>
<td>5/37</td>
<td>5*/33</td>
<td>8/41</td>
</tr>
<tr>
<td></td>
<td>(9)</td>
<td>(9)</td>
<td>(14)</td>
<td>(15)</td>
<td>(20)</td>
</tr>
<tr>
<td>p =</td>
<td>0.283</td>
<td>0.144</td>
<td>0.095</td>
<td>0.150</td>
<td>0.079</td>
</tr>
<tr>
<td>Carcinomas (%)</td>
<td>0/47</td>
<td>0/33</td>
<td>0/37</td>
<td>1/33</td>
<td>3*/43</td>
</tr>
<tr>
<td></td>
<td>(0)</td>
<td>(0)</td>
<td>(0)</td>
<td>(3)</td>
<td>(7)</td>
</tr>
<tr>
<td>p =</td>
<td>0.038*</td>
<td>-</td>
<td>-</td>
<td>0.079</td>
<td>0.056</td>
</tr>
<tr>
<td>Combined (%)</td>
<td>4/47</td>
<td>3/33</td>
<td>5/37</td>
<td>6/33</td>
<td>11/43</td>
</tr>
<tr>
<td></td>
<td>(9)</td>
<td>(9)</td>
<td>(14)</td>
<td>(18)</td>
<td>(26)</td>
</tr>
<tr>
<td>p =</td>
<td>0.100</td>
<td>0.139</td>
<td>0.093</td>
<td>0.068</td>
<td>0.022*</td>
</tr>
</tbody>
</table>

*Number of tumor bearing animals/Number of animals examined, excluding those that died or were sacrificed before observation of the first tumor.

First adenoma observed at week 70, dose 100 ppm.

First carcinoma observed at week 68, dose 1000 ppm.

Note: Interim sacrifice animals are not included in this analysis. There were no thyroid gland follicular cell tumors in any interim sacrifice animals.

Significance of trend denoted at control.

Significance of pair-wise comparison with control denoted at dose level.

If *, then p < 0.05. If **, then p < 0.01.
References


Thomas, D.G., N. Breslow, and J.J. Gart (1977) Trend and Homogeneity Analyses of Proportions and Life Table Data. Computers and Biomedical Research 10, 373-381.
013128

Chemical: Fluazinam

PC Code: 129098
HED File Code: 21200 CARC
Memo Date: 01/04/2001
File ID: TX014428
Accession Number: 412-02-0006

HED Records Reference Center
12/04/2001